Indication

What is an indication?

An indication is the specific disease, condition or symptom for which a medicine, medical device or surgical procedure is approved or authorised to be used. It defines the intended therapeutic purpose of the intervention and is established through scientific evidence and regulatory review.

An indication is often more precise than the name of a disease. Its wording may specify the patient population, disease stage or severity, biomarker status, treatment setting, line of therapy, combination treatment or previous treatment history. A product can have several indications if evidence supports its use in different clinical contexts.

Why does an indication matter in regulatory and medical affairs?

The approved indication sets the boundaries of the claims a company can make about a product. Regulatory, commercial and medical affairs teams must work from the exact authorised wording rather than treating a broad therapy area or disease name as the indication.

It affects evidence plans, scientific communications, educational materials, field team training and responses to healthcare professional questions. It also shapes which patients may be considered for treatment and how clinical evidence is presented at launch and throughout the product lifecycle.

How is an indication established in practice?

The proposed indication is developed from the population, intervention and outcomes studied in the clinical development programme. The sponsor submits evidence on efficacy, safety and benefit-risk, together with proposed wording, for regulatory review. The final indication may be narrower than the population originally studied or requested if the evidence does not support every proposed use.

Teams should read the complete wording alongside other parts of the product information. In practice, an indication may define:

• The disease, condition or symptom being treated, prevented or diagnosed.
• The eligible patient population, such as adults, children or patients with a particular biomarker.
• The stage, severity or subtype of disease.
• Whether the product is used alone or with another treatment.
• The treatment line or previous therapy requirements.
• Any restriction to a particular clinical setting.

Can one product have more than one indication?

Yes. A treatment may gain separate indications for different diseases, disease subtypes, patient groups, treatment lines or combinations. Each indication requires an appropriate evidence base and regulatory authorisation; evidence for one indication cannot automatically be assumed to support another.

Teams should therefore manage evidence and materials at indication level. Clinical endpoints, comparators, unmet need and relevant stakeholders may differ even when the same product or mechanism is involved. A new indication can also require a distinct value story, evidence plan and stakeholder strategy.

What is the difference between an approved indication and off-label use?

An approved indication appears in the authorised product information for the relevant jurisdiction. Off-label use is use outside those authorised terms, such as in a different condition, population, dose, route, treatment line or combination.

Clinical practice and scientific research may include off-label use, but it should not be presented as though it were approved. Companies need clear governance for handling unsolicited questions and scientific exchange, as the rules and permitted activities vary by jurisdiction and role.

How does an indication relate to market access and reimbursement?

Regulatory approval confirms that a product may be used for an indication, but it does not automatically establish reimbursement or routine access. Health technology assessment bodies and payers may assess value for a more specific population, compare the product with local standards of care, or apply conditions to funding. Pricing and reimbursement decisions can therefore differ between indications for the same product.

The indication sits next to, but is not the same as, the label, treatment setting, target population or reimbursed population. The label contains the wider authorised product information; the indication states the approved therapeutic use; and the reimbursed population defines who is funded in practice.